Join the Webcast: Novartis Dialogue to Explore Solutions to the Rise of Chronic Diseases in the Developing World

Join the Webcast: Novartis Dialogue to Explore Solutions to the Rise of Chronic Diseases in the Developing World

The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.

Thursday, November 24, 2016 - 2:05am

November 24, 2016 /3BL Media/ - The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.

Novartis Access and the Novartis Foundation will be discussing chronic diseases with experts from academia and non-profit organizations speaking and attending.

Speakers and panelists will include representatives from the World Health Organization, PATH, Pink Ribbon Red Ribbon, the London School of Hygiene & Tropical Medicine, Boston University and Emory University, as well as government delegates.  Joerg Reinhardt, Novartis Chairman, will also deliver a keynote address.


In the morning, in collaboration with the Centre for Global Non-Communicable Diseases of the London School of Hygiene & Tropical Medicine, the Novartis Foundation will explore person-centered approaches to improving management and care for hypertension and its complications in lower-income areas.

In the afternoon, Novartis Access will present findings and learnings from the first year of implementation of an innovative social business approach to treat chronic diseases in lower-income countries. Speakers from both Novartis and its partners will present findings and discuss how they addressed challenges in the implementation, one year into the program.

We hope to have an engaging and interactive session. Join the conversation on Twitter: @Novartis @NovartisFDN #NovartisAccess #talkingNCDs. The webcast  will be available to view on demand following the event on and

Event details

Improving care for chronic patients in lower-income countries: the patient journey    

November 29, 2016
09:30 – 15:30 CET


Join the conversation on Twitter: @Novartis @NovartisFDN #NovartisAccess #talkingNCDs

Watch the webcast  on demand following the event on and



Ann Aerts, Head of the Novartis Foundation


Peter Piot, Director, London School of Hygiene & Tropical Medicine (moderator)


Integrated people-centered health services
Edward Kelley, Director, Department of Service Delivery and Safety, World Health Organization


Case studies followed by facilitated group discussion

  • Truong Bui, Project Director, Ho Chi Minh City Communities for Healthy Hearts, PATH
  • Nitin Barekere, Group Head - HR & Organization Learning, Narayana Health
  • Paddy Partridge, Regional Manager Africa BIMA mobile micro-insurance and health  
  • Alma Adler, Epidemiologist at London School of Hygiene & Tropical Medicine


The Novartis commitment to expanding access to healthcare
Joerg Reinhardt, Chairman of Novartis and of the Novartis Foundation Board of Trustees




Harald Nusser, Head Novartis Social Business


Key note speech (title TBC)
Amit N. Thakker, Chairman Kenya Healthcare Federation


Facilitated group discussion with moderator / panel

Vikas Tibrewala, independent consultant and former Faculty Member at INSEAD (moderator)

  •  Akudo Anyanwu, Director Development,  Emory Vaccine Center, Emory University
  • Richard Laing, Professor, Boston University
  • Nelson Muriu, County Director of Health Services, Nyeri County, Kenya
  • Celina Schocken, CEO Pink Ribbon Red Ribbon
  • Harald Nusser, Head Novartis Social Business


Closing remarks
Vikas Tibrewala


About the Novartis Foundation

The Novartis Foundation is a philanthropic organization pioneering innovative healthcare models that can have a transformational impact on the health of the poorest populations. We work hand-in-hand with our local and global partners to catalyze scalable and sustainable healthcare models to improve access and health outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing on interventions that aim to interrupt transmission. Everything we do is grounded in evidence and innovation, and our work is a continuous cycle of evaluation, adaptation and application. In 2015, the operational budget for the foundation was CHF 12 million and our programs reached 4.5 million people.

For more information, please visit:

Novartis Foundation is on Twitter. Sign up to follow @NovartisFDN at

About Novartis Access
Novartis Access is a Group-wide program to help fight chronic diseases in lower-income countries. The Novartis Access portfolio focuses on affordability and availability of 15 on- and off-patent Novartis medicines addressing key diseases areas – cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. The portfolio is offered as a basket to governments, non-governmental organizations (NGOs) and other public-sector customers at a price of USD 1 per treatment per month. Beyond the portfolio of medicines, Novartis Access offers capacity-building activities to support healthcare systems in preventing, diagnosing and treating NCDs. We are striving to roll out the program in 30 countries in the coming years – depending on governmental and stakeholder demand – aiming to reach 20 million patients per year by 2020.

Novartis Access is integrated in Novartis Social Business, a unit which includes the Novartis Malaria Initiative and the Novartis Healthy Family programs. This unit is operationally managed by Sandoz, the Novartis generics and biosimilars division.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in approximately 180 countries around the world. For more information, please visit

Novartis is on Twitter. Sign up to follow @Novartis at (link is external)

Novartis Media Relations
Central media line: +41 61 324 2200

Niamh Johnston
Novartis External Communications
+41 61 69 68942 (direct)
+41 79 60 02894 (mobile)

Kiara Barnes
Novartis Foundation
+41 61 696 8181 (direct)
+41 79 724 7037 (mobile)